Montana's implementation rules for Senate Bill 535 are now active, enabling experimental treatment review boards and licensed clinics to evaluate and administer post-Phase 1 therapies outside the traditional FDA approval pathway. This regulatory framework represents a shift toward decentralized oversight of early-stage interventions, with potential implications for how investigational longevity therapies reach patients.
Key Points
- Montana operational rules enable Phase 1+ therapy access through licensed ETRBs
- Infinita established first review board with aging research experts
- Decentralized model separates safety review from centralized federal approval
Longevity Analysis
The Montana framework creates a structured alternative to standard FDA timelines for accessing experimental therapies, particularly relevant for interventions targeting aging biology. This requires practitioners and patients to become more sophisticated in interpreting safety data and understanding risk-benefit profiles independently—a shift that demands improved ability to decode what Phase 1 completion actually communicates about a therapy's safety profile. The regulatory model itself does not accelerate biological results; it accelerates access. Success depends on how well review boards and treatment centers distinguish genuine safety signals from statistical noise, and whether patients can make informed decisions based on incomplete long-term efficacy data. This is simultaneously a test of decentralized oversight and a reminder that regulatory approval velocity is separate from biological benefit.
Original published by Longevity.Technology, by Kyle Umipig.